TABLE 1.

Treatment of P. berghei-infected CD1 mice with different formulations of halofantrine (4-day test)

TreatmentDay 4Day 7MSTe (days)
% ParasitemiacRBC (106/μl)% ParasitemiacRBC (106/μl)
Control52.6 ± 13.8 (31-71)2.5 ± 0.737.6 ± 6.1 (31-44)2.1 ± 0.67.1 (5-10)
Unloaded PLA-POLOX NCNDgNDNDND6.6 (5-9)
Unloaded PLA-PEG 20-30 NC50.4 ± 17.0 (21-69)2.6 ± 0.831.1 ± 19.5 (27-52)2.0 ± 0.413.6 (7-26)
Halofantrine formulations
    i.v. solutiona0.5 ± 0.8 (0-2.0)d5.5 ± 1.11.1 ± 0.5 (0-1.5)d7.8 ± 1.1>60 (n = 10)
    PLA-POLOX NCa0.5 ± 0.9 (0-2.5)d6.0 ± 1.30.9 ± 0.9 (0-2.5)d8.1 ± 1.0>60 (n = 8)f
    PLA-PEG 20-30 NCa0.5 ± 0.5 (0-1.5)d4.9 ± 0.21.3 ± 1.2 (0-4)d7.0 ± 0.7>60 (n = 10)
Oral suspensionb0.4 ± 0.7 (0-1.6)d4.9 ± 0.70.3 ± 0.6 (0-1.6)d8.0 ± 0.7>60 (n = 10)
  • a Mice were treated i.v. with 1 mg/kg/day in a 4-day-test.

  • b Mice were treated orally with 4 mg/kg/day in a 4-day-test.

  • c Values are mean parasitemia ± standard deviations (95% confidence intervals are in parentheses).

  • d Significantly different from controls in one-way analysis of variance (95% confidence intervals).

  • e MST, mean survival time. The range or number of surviving mice is in parentheses.

  • f One mouse each died on days 15 and 28.

  • g ND, not determined.